Clinical Trial Update: S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing S1 + paclitaxel + bevacizumab vs S1 + oxaliplatin as first-line therapy for metastatic gastric adenocarcinoma with malignant as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• S1 + Oxaliplatin
• S1 + Paclitaxel (IV&IP) + Bevacizumab (IP)

Snippet

Sponsor: China Medical University, China | Conditions: Metastatic Gastric Adenocarcinoma | Phase 2 | Status: UNKNOWN